INTERNATIONAL BIOTECHNOLOGY TRUST PLC
Portfolio Update as at 31 January 2015
|
Net Assets |
£234m |
|
Net Assets per share |
554p |
|
Share price |
508p |
|
Total value of unquoted investments |
£20m |
|
Total number of portfolio companies |
83 |
Top Ten Holdings
|
Company Name |
% NAV |
|
Celgene |
7.1 |
|
Gilead |
7.1 |
|
Biogen-Idec |
6.7 |
|
Amgen |
5.2 |
|
Chimerix |
4.9 |
|
Alexion |
3.3 |
|
Vertex |
3.1 |
|
Pharmacyclics |
3.0 |
|
Ophthotech |
2.9 |
|
Regeneron |
2.7 |
|
|
----------- |
|
Total |
46.0 |
|
Portfolio Profitability |
% NAV |
|
Profitable |
52 |
|
Turning Profitable 2015 |
5 |
|
Unprofitable |
43 |
|
|
----------- |
|
Total |
100 |
|
Geographical Allocation |
% NAV |
|
US & Canada |
88 |
|
Europe & UK |
12 |
|
|
----------- |
|
Total |
100 |
|
Quoted/Unquoted Allocation |
% NAV |
|
Quoted |
92 |
|
Unquoted |
8 |
|
|
----------- |
|
Total |
100 |
BNP Paribas Secretarial Services Limited
Company Secretary
24 FEBRUARY 2015